MACOP-B regimen followed by involved-field radiation therapy in early-stage aggressive non-Hodgkin's lymphoma patients: 14-year update results.

Abstract

A single-center, retrospective study was conducted to evaluate therapeutic results of the MACOP-B third-generation chemotherapy regimen followed by involved-field radiation therapy in a stage I-II aggressive non-Hodgkin's lymphoma (NHL) patients. From 1986 to 1995, 118 consecutive patients with the diagnosis of aggressive NHL, stage I-IE or II-IIE, with or without bulky disease were treated with MACOP-B regimen followed, when appropriate, by 30-36 Gy involved-field radiation therapy. The complete response (CR) rate was 95% after the combined modality treatment (97% for stage I-IE and 93% for stage II-IIE). Patients with bulky disease had a CR rate of 92%. Treatment was well tolerated and no deaths occurred from acute toxicity. After a median follow-up of 68 months, 24 (21%) patients relapsed. The 14-year projected relapse-free and overall survival rates were 78% and d 69%, respectively. MACOP-B regimen with/without involved-field radiation therapy provides a safe and effective combined modality treatment for early-stage aggressive NHL, with the possibility to definitively cure two thirds of the patients.

• Authors: P L Zinzani, V Stefoni, M Tani, E Barbieri, P Albertini, E Vigna, F Gherlinzoni, L Alinari, A Galuppi, S Pileri, L Babini, S Tura
• Journal: Leukemia & lymphoma (Leuk Lymphoma) 2001 Sep-Oct Vol. 42 Issue 5 Pg. 989-95 ISSN: 1042-8194 [Print] United States
• PMID: 11697654 (Publication Type: Journal Article)

Chemical References

• Bleomycin
• Vincristine
• Doxorubicin
• Cyclophosphamide
• Prednisolone
• Methotrexate

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use, toxicity)
• Bleomycin (administration & dosage)
• Combined Modality Therapy
• Cyclophosphamide (administration & dosage)
• Doxorubicin (administration & dosage)
• Female
• Follow-Up Studies
• Humans
• Lymphoma, Non-Hodgkin (complications, mortality, therapy)
• Male
• Methotrexate (administration & dosage)
• Middle Aged
• Prednisolone (administration & dosage)
• Radiotherapy, Adjuvant
• Retrospective Studies
• Survival Analysis
• Vincristine (administration & dosage)